Yeryoy navigation

The agency places a partial clinical hold on the phase 3 PRESERVE-003 trial due to varying results between the squamous and nonsquamous NSCLC cohorts.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Investigators are assessing the feasibility, safety, and efficacy of MTX110 for patients with recurrent glioblastoma as part of the phase 1 MAGIC-1 study.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Data from the phase 3 SPOTLIGHT trial and the phase 3 GLOW trial supported the approval of zolbetuximab plus chemotherapy in this indication.

Adolescents and young adults with cancer more commonly experience financial toxicity and unmet social needs.